Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1957 1
1961 1
1970 1
1971 2
1973 2
1974 2
1975 2
1976 4
1977 1
1978 2
1979 6
1981 2
1982 5
1983 1
1984 6
1985 3
1986 6
1987 6
1988 5
1989 7
1990 7
1991 1
1992 3
1993 2
1994 5
1995 6
1997 6
1998 2
1999 4
2000 6
2001 10
2002 13
2003 14
2004 27
2005 14
2006 12
2007 16
2008 25
2009 18
2010 18
2011 27
2012 27
2013 23
2014 22
2015 21
2016 33
2017 45
2018 36
2019 50
2020 34
2021 63
2022 29
Text availability
Article attribute
Article type
Publication date

Search Results

604 results
Results by year
Filters applied: . Clear all
Page 1
Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.
Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, Shirai T, Kanaya S, Ito Y, Kim KS, Nomura T, Suzuki T, Nishioka K, Ando S, Ejima K, Koizumi Y, Tanaka T, Aoki S, Kuramochi K, Suzuki T, Hashiguchi T, Maenaka K, Matano T, Muramatsu M, Saijo M, Aihara K, Iwami S, Takeda M, McKeating JA, Wakita T. Ohashi H, et al. Among authors: koizumi y. iScience. 2021 Apr 23;24(4):102367. doi: 10.1016/j.isci.2021.102367. Epub 2021 Mar 26. iScience. 2021. PMID: 33817567 Free PMC article.
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan). Hiraoka A, et al. Among authors: koizumi y. Cancer Rep (Hoboken). 2022 Feb;5(2):e1464. doi: 10.1002/cnr2.1464. Epub 2021 Jun 11. Cancer Rep (Hoboken). 2022. PMID: 34114752 Free PMC article.
Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19.
Sakanashi D, Asai N, Nakamura A, Miyazaki N, Kawamoto Y, Ohno T, Yamada A, Koita I, Suematsu H, Hagihara M, Shiota A, Kurumiya A, Sakata M, Kato S, Muramatsu Y, Koizumi Y, Kishino T, Ohashi W, Yamagishi Y, Mikamo H. Sakanashi D, et al. Among authors: koizumi y. J Infect Chemother. 2021 Jan;27(1):126-129. doi: 10.1016/j.jiac.2020.09.027. Epub 2020 Sep 30. J Infect Chemother. 2021. PMID: 33060046 Free PMC article.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan. Hiraoka A, et al. Among authors: koizumi y. Hepatol Res. 2022 Mar;52(3):308-316. doi: 10.1111/hepr.13734. Epub 2021 Dec 2. Hepatol Res. 2022. PMID: 34799975
Pseudohypoparathyroidism Causing Multiple Brain Calcifications.
Kobayashi Y, Tsuyuzaki J, Koizumi Y. Kobayashi Y, et al. Among authors: koizumi y. Intern Med. 2018 Jan 1;57(1):153-154. doi: 10.2169/internalmedicine.8926-17. Epub 2017 Oct 16. Intern Med. 2018. PMID: 29033417 Free PMC article. No abstract available.
604 results